Myocardial Ischemia pipeline Research Monitor, 2020- Drugs, Companies, Clinical Trials, R&D pipeline updates, status and outlook

July 2020 | 61 pages | ID: M5F6C067ED33EN
VPAResearch

Abstracts

2020 Myocardial Ischemia PIPELINE HIGHLIGHTS
Myocardial Ischemia is one of the widely researched conditions during 2020 with 11 companies actively focusing on realizing pipeline’s potential. Development of Myocardial Ischemia medicines is identified as integral to the strategy of the majority of companies operating in the industry.
Global Myocardial Ischemia market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Myocardial Ischemia.

Good progress is anticipated during 2020 and 2021 with Myocardial Ischemia pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Myocardial Ischemia pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.
Myocardial Ischemia DRUG DEVELOPMENT PIPELINE OVERVIEW
The “Myocardial Ischemia pipeline Research Monitor, 2020” report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.
This Myocardial Ischemia pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.

The competitive intelligence report on Myocardial Ischemia presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Myocardial Ischemia pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.
Myocardial Ischemia DRUG PROFILES
Myocardial Ischemia development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided-

• Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others.
• Phase of development
• Mechanism of Action
• Route of Administration
• Companies involved including originator, licensing companies, developer, investors, and others
• New molecular entity details
• Orphan drug designation and other special status provided by regulators

Myocardial Ischemia COMPANY PROFILES

Both small size and large size pharmaceutical companies are investing their resources in Myocardial Ischemia drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Myocardial Ischemia. Partnerships and acquisitions are also increasingly observed in the pipeline.

This research report presents an analysis of 11 Myocardial Ischemia companies including company overview, key snapshot, contact information, and their strategies on accelerating Myocardial Ischemia pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.

Companies analyzed in the report include- Angionetics Inc, AstraZeneca Plc, Cadrock Pty Ltd, Caladrius Biosciences Inc, Cellmid Ltd, Chrysalis BioTherapeutics Inc, CohBar Inc, Everon Biosciences Inc, NoNO Inc, Q BioMed Inc, Vasade Biosciences Inc

REASONS TO BUY

• The current market conditions are forcing companies and investors worldwide to prioritize their investments and accelerate pipeline candidates only through careful quantitative assessment.
• This research work assists decision makers in pharmaceutical companies towards successful pipeline development through critically evaluated pipeline data
• Buyers can identify most promising drug candidates for treatment of Myocardial Ischemia
• It allows users to strengthen their pipeline through acquisitions, licensing and collaborations
• Users can estimate possible delays in the delivery of pipeline or launch of new products
• Stay ahead of competition through understanding their pipeline progression, strategies and outlook
• The report details all the pipeline candidates under investigation in various stages of development from Phase I through to Phase III to enable business development managers to understand the impact of new launches.
• Optimize your licensing and technology transfer strategies through identification of prospect partners

Contents

1. INTRODUCTION TO MYOCARDIAL ISCHEMIA

1.1 Myocardial Ischemia- Disease overview
1.2 Myocardial Ischemia- Market Size
1.3 Myocardial Ischemia- Companies Involved

2. MYOCARDIAL ISCHEMIA PIPELINE SNAPSHOT- 2020

2.1 Myocardial Ischemia Pipeline by Phase
2.2 Myocardial Ischemia Pipeline by Mechanism of Action
2.3 Myocardial Ischemia Pipeline by Route of Administration
2.4 Myocardial Ischemia Pipeline- New Molecular Entities
2.5 Myocardial Ischemia Pipeline- Orphan Drug Designation/ Special Designation

3. MYOCARDIAL ISCHEMIA DRUG PROFILES

3.1 Current Status
3.2 Myocardial Ischemia Drug Snapshot
3.3 Myocardial Ischemia Therapeutic Candidates- Originator/Licensor
3.4 Route of Administration
3.5 Mechanism of Action
3.6 NME
4.1 Angionetics Inc Myocardial Ischemia Pipeline Insights and Clinical Trials
4.2 AstraZeneca Plc Myocardial Ischemia Pipeline Insights and Clinical Trials
4.3 Cadrock Pty Ltd Myocardial Ischemia Pipeline Insights and Clinical Trials
4.4 Caladrius Biosciences Inc Myocardial Ischemia Pipeline Insights and Clinical Trials
4.5 Cellmid Ltd Myocardial Ischemia Pipeline Insights and Clinical Trials
4.6 Chrysalis BioTherapeutics Inc Myocardial Ischemia Pipeline Insights and Clinical Trials
4.7 CohBar Inc Myocardial Ischemia Pipeline Insights and Clinical Trials
4.8 Everon Biosciences Inc Myocardial Ischemia Pipeline Insights and Clinical Trials
4.9 NoNO Inc Myocardial Ischemia Pipeline Insights and Clinical Trials
4.10 Q BioMed Inc Myocardial Ischemia Pipeline Insights and Clinical Trials
4.11 Vasade Biosciences Inc Myocardial Ischemia Pipeline Insights and Clinical Trials

5. MYOCARDIAL ISCHEMIA MARKET NEWS AND UPDATES

6. APPENDIX

6.1 Sources and Methodology
6.2 Contact Information